Novozymes prevails in patent trial against Danisco
Kristian Merser, general counsel in Novozymes states: "We are very pleased with the decision but we are obviously annoyed by the harm the patent infringement has caused on our market for biofuel enzymes. It´s very satisfactory that the court agreed that our patent is valid and has been infringed - considering the large amount of resources we use on research, development and patenting."
Danisco announced that the company has withdrawn the product that infringed Novozymes' patent (Spezyme(R) Ethyl) from the market. The size of the damages will be decided in the fall. Novozymes has claimed several million US dollars in damages for loss of profits.
Most read news
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.